Loading
A phase 1/2 trial of KRT-232, Acalabrutinib in diffuse large b-cell lymphoma and hodgkin lymphoma, run by Kartos Therapeutics, Inc., now recruiting.
Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL is a phase 1/2 interventional study registered as NCT04502394 by Kartos Therapeutics, Inc., with 84 participants planned, started 2021-02-23 and due to reach its primary completion in 2022-10. Interventions recorded: KRT-232, acalabrutinib. Conditions listed: Diffuse Large B Cell Lymphoma, Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Kartos Therapeutics, KRT-232, Small-molecule kinase inhibitors.
Shares Kartos Therapeutics, KRT-232.
Shares Acalabrutinib, Hodgkin lymphoma, Non-Hodgkin lymphoma (all types), Small-molecule kinase inhibitors.
Shares Acalabrutinib, Diffuse large B-cell lymphoma, Small-molecule kinase inhibitors.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/